Skip to main content


Latest articles

03-07-2020 | Rheumatology | News | Article

EMA approves subcutaneous infliximab for PsA, ankylosing spondylitis

Click through for more details about this expanded indication

03-07-2020 | Rheumatology | News | Article

Study demonstrates real-world effectiveness of certolizumab pegol for axSpA

Treatment with certolizumab pegol is beneficial for patients with axial spondyloarthritis in real-world clinical practice, suggest findings from the CIMAX study.

02-07-2020 | Rheumatology | News | Article

Colchicine shows potential for COVID-19

Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.

01-07-2020 | Rheumatology | News | Article

Heightened risk for self-harm with some rheumatic diseases

Patients with rheumatic diseases, particularly fibromyalgia, have elevated rates of self-harm, according to data from the Clinical Practice Research Datalink.

01-07-2020 | Rheumatology | News | Article

ACR clarifies support for telemedicine in rheumatology during and after COVID-19

The American College of Rheumatology has issued a position statement supporting the use of telemedicine during and after the COVID-19 pandemic.

30-06-2020 | Rheumatology | News | Article

Age at biologic DMARD initiation impacts adverse event risk

The likelihood of experiencing an adverse event after initiating treatment with a first biologic DMARD increases with age and is higher in women than men, show data from a real-world study among people with rheumatic diseases.

29-06-2020 | Rheumatology | News | Article

COVID-19 lockdown has ‘significant consequences’ for SpA patients

Home confinement during the COVID-19 pandemic is associated with a reduction in medication intake and a worsening of disease activity among patients with spondyloarthritis, survey results suggest.

29-06-2020 | Rheumatology | News | Article

COVID-19: Support for further investigation of tocilizumab

Add-on treatment with the IL-6 inhibitor tocilizumab may improve outcomes for patients with severe COVID-19, suggest findings from two retrospective cohort studies.

26-06-2020 | Rheumatology | News | Article

Noninferiority of diacerein to celecoxib demonstrated for knee OA pain

Diacerein has comparable efficacy to celecoxib for pain reduction in patients with moderate-to-severe symptomatic knee osteoarthritis and is well tolerated, suggest study findings reported in Rheumatology.

25-06-2020 | Rheumatology | News | Article

Age, comorbidities linked to poor COVID-19 outcomes in patients with rheumatic diseases

Rheumatic diseases and their treatments may not be associated with outcomes of SARS-CoV-2 infection, but older age and comorbidities are likely risk factors for a severe COVID-19 disease course in rheumatology patients, suggest findings from two studies.

24-06-2020 | Rheumatology | Highlight | Article

​​​​​​​Cardiovascular safety of romosozumab warrants ‘rigorous assessment’

Romosozumab and other sclerostin inhibitors may increase cardiovascular risk, suggests evidence from a meta-analysis of randomized trials and a study of genetic variants that mimic pharmacologic inhibition of sclerostin.

24-06-2020 | Rheumatology | News | Article

BMI impacts TNF inhibitor retention in people with RA

Both underweight and obese people with rheumatoid arthritis are at increased risk for discontinuing TNF inhibitor treatment earlier than their normal weight counterparts, real-world study findings indicate.

23-06-2020 | Rheumatology | News | Article

COVID-19: FDA revokes Emergency Use Authorization for hydroxychloroquine

Click through for further details on this announcement

23-06-2020 | Rheumatology | News | Article

Optimal biologic therapy for RA varies by age

The outcomes of patients with rheumatoid arthritis could be improved by using the biologic DMARD option most appropriate to the age group, say Japanese researchers who assessed retention rates by age.

22-06-2020 | Rheumatology | News | Article

COVID-19: Telemedicine feasible for PsA management

Telehealth is a feasible approach for managing patients with psoriatic arthritis during the COVID-19 pandemic, Italian researchers report.

22-06-2020 | Rheumatology | News | Article

COVID-19 hospitalization, mortality rates in RMD patients may not differ from general population

Preliminary findings from the Spanish BIOBADASER registry suggest that patients with rheumatic and musculoskeletal diseases  may not have an elevated risk for COVID-19 hospitalization or mortality compared with the general population.

19-06-2020 | Rheumatology | News | Article

COVID-19: ACR issues draft pediatric guidance

The American College of Rheumatology has issued two draft clinical guidance documents for the management of pediatric patients during the COVID-19 pandemic.

19-06-2020 | Rheumatology | News | Article

Consistent benefits of sarilumab across RA subpopulations

Sarilumab treatment provides consistent benefits for a broad range of patients with rheumatoid arthritis (RA), suggests a subgroup analysis of data from phase 3 trials.

18-06-2020 | Rheumatology | News | Article

FDA approves canakinumab for adult-onset Still’s disease

Click through for more information on this announcement

17-06-2020 | Rheumatology | News | Article

Support for further investigation of canakinumab for COVID-19

Preliminary data suggest that the interleukin-1β inhibitor canakinumab may warrant further investigation as a treatment option for patients with COVID-19 who experience a hyper-inflammatory response.

Image Credits